Next Article in Journal
CASMI—The Small Molecule Identification Process from a Birmingham Perspective
Next Article in Special Issue
Studies of Secondary Melanoma on C57BL/6J Mouse Liver Using 1H NMR Metabolomics
Previous Article in Journal
Metabolic and Transcriptional Reprogramming in Developing Soybean (Glycine max) Embryos
Previous Article in Special Issue
Getting Your Peaks in Line: A Review of Alignment Methods for NMR Spectral Data
Metabolites 2013, 3(2), 373-396; doi:10.3390/metabo3020373
Review

The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs?

 and *
Received: 8 February 2013; in revised form: 7 May 2013 / Accepted: 10 May 2013 / Published: 17 May 2013
(This article belongs to the Special Issue NMR-based Metabolomics and Its Application)
View Full-Text   |   Download PDF [803 KB, uploaded 17 May 2013]   |   Browse Figures
Abstract: There has been a recent shift in how cancers are defined, where tumors are no longer simply classified by their tissue origin, but also by their molecular characteristics. Furthermore, personalized medicine has become a popular term and it could start to play an important role in future medical care. However, today, a “one size fits all” approach is still the most common form of cancer treatment. In this mini-review paper, we report on the role of nuclear magnetic resonance (NMR) metabolomics in drug development and in personalized medicine. NMR spectroscopy has successfully been used to evaluate current and potential therapies, both single-agents and combination therapies, to analyze toxicology, optimal dose, resistance, sensitivity, and biological mechanisms. It can also provide biological insight on tumor subtypes and their different responses to drugs, and indicate which patients are most likely to experience off-target effects and predict characteristics for treatment efficacy. Identifying pre-treatment metabolic profiles that correlate to these events could significantly improve how we view and treat tumors. We also briefly discuss several targeted cancer drugs that have been studied by metabolomics. We conclude that NMR technology provides a key platform in metabolomics that is well-positioned to play a crucial role in realizing the ultimate goal of better tailored cancer medicine.
Keywords: NMR; metabolomics; cancer; personalized medicine; drug toxicity; targeted drugs NMR; metabolomics; cancer; personalized medicine; drug toxicity; targeted drugs
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Palmnas, M.S.; Vogel, H.J. The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs? Metabolites 2013, 3, 373-396.

AMA Style

Palmnas MS, Vogel HJ. The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs? Metabolites. 2013; 3(2):373-396.

Chicago/Turabian Style

Palmnas, Marie S.; Vogel, Hans J. 2013. "The Future of NMR Metabolomics in Cancer Therapy: Towards Personalizing Treatment and Developing Targeted Drugs?" Metabolites 3, no. 2: 373-396.


Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert